Navigation Links
Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
Date:5/14/2009

- Data on BIBW 2992, an Irreversible, Dual EGFR / HER2 Tyrosine Kinase Inhibitor, Suggests Activity in Second-line Treatment of NSCLC Patients with EGFR Activating Mutations - (1,2)

-The First Presentation of Data on BIBF 1120 in Ovarian Cancer-

RIDGEFIELD, Conn., May 14 /PRNewswire/ -- Boehringer Ingelheim will present new data on the company's two lead oncology compounds, BIBW 2992 and BIBF 1120 at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO), the company announced today. Two studies in the LUX-Lung clinical development program for BIBW 2992 and a Phase II study of BIBF 1120 in ovarian cancer patients will be presented.

LUX-Lung 2 Interim Results

Interim Phase II data from the LUX-Lung 2 study suggest BIBW 2992 has anti-tumor activity in advanced, second-line, non-small cell lung cancer (NSCLC) patients who have epidermal growth factor receptor (EGFR) mutations.(2)

"Lung cancer kills more people than any other cancer.(3) The LUX-Lung 1 and 2 studies represent an opportunity to investigate BIBW 2992 across a range of different patient populations," said Dr. Manfred Haehl, corporate senior vice president, Medicine, Boehringer Ingelheim. "The preliminary data from the LUX-Lung 2 study suggests that BIBW 2992 may have activity in the second-line setting among NSCLC patients with EGFR mutations, which is encouraging news."(2)

BIBW 2992 is an orally-administered, irreversible dual inhibitor of the epidermal growth factor receptor (EGFR) and human epithelial receptor 2 (HER2) tyrosine kinases.(1) It is the first irreversible EGFR-TKI (tyrosine kinase inhibitor) to reach Phase III for third/fourth-line NSCLC.(4)

In the emerging era of personalized cancer medicine, Boehringer Ingelheim is one of the first companies to prospectively identify appropriate patients for clinical trials based on bioma
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
5. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
10. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
11. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
(Date:1/14/2014)... 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System ... accompanying instrumentation to place and insert the screw accurately ... tissue (e.g. ligament) repair or reconstruction as it holds ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) The ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
(Date:4/18/2014)... Research Institute at Virginia Mason (BRI) recently received a ... metastatic breast cancer reduces both the growth of primary ... have found in models of the disease that blocking ... percent and can keep the tumor from metastasizing or ... comes from the National Cancer Institute of the National ...
(Date:4/18/2014)... in French . ... and regenerative medicine. A team led by Ludwik Leibler ... Tech) and Didier Letourneur from the Laboratoire Recherche Vasculaire ... demonstrated that the principle of adhesion by aqueous solutions ... soft-tissue organs and tissues. This easy-to-use gluing method has ...
(Date:4/17/2014)... inflammation in non-cancerous prostate tissue may have nearly twice ... with no inflammation, according to results of a new ... Cancer Center. , The link between persistent inflammation and ... prostate cancer those with a Gleason score between ... most aggressive and rapidly growing prostate cancers. , "What ...
(Date:4/17/2014)... of the most popular vaccine brands for children may ... be overlooking some cost factors when choosing vaccines, driving ... option, according to a new study by University of ... can be driven by numerous factors," says Sheldon H. ... of computer science and of mathematics at the U. ...
(Date:4/17/2014)... University of California, San Diego School of Medicine report ... suffered a recent major loss are more likely to ... The study is published in this month,s issue of ... Because compassionate behaviors are associated with better health and ... into ways to improve the outcomes of individuals whose ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2
... , ... leaders Earn Prestigious Parallels Partner Awards for innovation, branding, inspiration and growth at the ... ... , today announced the winners of its inaugural Partner Awards at the Parallels Summit ...
... , , ... ... ... ...
... a cruel, hereditary condition that leads to severe physical and ... are no treatments to slow down or stop it. ... not show symptoms until late in life. In a ... Stephen Ferguson and Fabiola Ribeiro of Robarts Research Institute at ...
... ... a business process consultant, life coach and self improvement veteran of more ... coaches to market their services, as well as an Ask-a-Coach corner where ... of information where coaches, clients and visitors may freely interact. ...
... ... ... ... ...
... proteins in premalignant oral lesions may predict oral ... SIBLINGs, or Small Integrin-Binding Ligand N-linked Glycoproteins, ... mineralize bone but can also spread cancer. SIBLINGs ... colon and prostate. "Several years ago we ...
Cached Medicine News:Health News:Winners are Grinners at the Inaugural Parallels Partner Awards 2Health News:Winners are Grinners at the Inaugural Parallels Partner Awards 3Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 2Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 3Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 4Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 5Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 6Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 7Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 8Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 9Health News:Protecting the brain from a deadly genetic disease 2Health News:Improvement Now Made Easier With Self-Improvement-Life-Coach.com 2Health News:Improvement Now Made Easier With Self-Improvement-Life-Coach.com 3Health News:Improvement Now Made Easier With Self-Improvement-Life-Coach.com 4Health News:ChildCare Education Institute Supports the First Lady's Efforts to Reduce Childhood Obesity 2Health News:ChildCare Education Institute Supports the First Lady's Efforts to Reduce Childhood Obesity 3Health News:ChildCare Education Institute Supports the First Lady's Efforts to Reduce Childhood Obesity 4Health News:ChildCare Education Institute Supports the First Lady's Efforts to Reduce Childhood Obesity 5Health News:SIBLING proteins may predict oral cancer 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: